JP2024519845A5 - - Google Patents
Info
- Publication number
- JP2024519845A5 JP2024519845A5 JP2023571509A JP2023571509A JP2024519845A5 JP 2024519845 A5 JP2024519845 A5 JP 2024519845A5 JP 2023571509 A JP2023571509 A JP 2023571509A JP 2023571509 A JP2023571509 A JP 2023571509A JP 2024519845 A5 JP2024519845 A5 JP 2024519845A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitors
- pharmaceutically acceptable
- yap
- taz
- tead
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163190766P | 2021-05-19 | 2021-05-19 | |
| US63/190,766 | 2021-05-19 | ||
| PCT/US2022/072452 WO2022246459A1 (en) | 2021-05-19 | 2022-05-19 | Combination therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024519845A JP2024519845A (ja) | 2024-05-21 |
| JP2024519845A5 true JP2024519845A5 (cg-RX-API-DMAC7.html) | 2025-05-27 |
Family
ID=82492721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023571509A Pending JP2024519845A (ja) | 2021-05-19 | 2022-05-19 | 併用療法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240148733A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4340883A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024519845A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117337193A (cg-RX-API-DMAC7.html) |
| AR (1) | AR125921A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW202313048A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022246459A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240374571A1 (en) * | 2021-09-01 | 2024-11-14 | Novartis Ag | Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers |
| CN119968359A (zh) | 2022-09-29 | 2025-05-09 | 英矽智能科技知识产权有限公司 | Tead抑制剂及其使用方法 |
| CN120659608A (zh) * | 2023-02-23 | 2025-09-16 | 诺华股份有限公司 | 用于治疗癌症的tead抑制剂和kras g12d抑制剂组合 |
| JP2026513205A (ja) * | 2023-03-27 | 2026-04-23 | ビバーチェ セラピューティクス,インク. | Hippo-yap経路モジュレーターの合成およびその多形体 |
| WO2025054190A1 (en) * | 2023-09-05 | 2025-03-13 | Vivace Therapeutics, Inc. | Pharmaceutical formulations and dosing schedules of a yap/taz-tead inhibitor |
| WO2025101655A1 (en) * | 2023-11-08 | 2025-05-15 | Vivace Therapeutics, Inc. | Compounds for modulating yap-tead/hippo pathway |
| WO2025122956A1 (en) * | 2023-12-08 | 2025-06-12 | Vivace Therapeutics, Inc. | Combination therapy |
| US12662707B2 (en) | 2024-01-24 | 2026-06-23 | The Trustees Of Columbia University In The City Of New York | MYC amplification drives resistance to pan-RAS inhibitors in pancreatic cancer |
| WO2026112349A1 (en) * | 2024-11-22 | 2026-05-28 | Vivace Therapeutics, Inc. | Methods and systems for patient selection and treatment |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA127968C2 (uk) * | 2017-05-22 | 2024-02-28 | Емджен Інк. | Інгібітори g12c kras і способи їх застосування |
| WO2019040380A1 (en) * | 2017-08-21 | 2019-02-28 | Vivace Therapeutics, Inc. | BENZOSULFONYL COMPOUNDS |
| CA3082579A1 (en) * | 2017-11-15 | 2019-05-23 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| EP3877356A4 (en) * | 2018-11-09 | 2022-06-22 | Vivace Therapeutics, Inc. | BICYCLIC LINKS |
| WO2020097537A2 (en) * | 2018-11-09 | 2020-05-14 | Genentech, Inc. | Fused ring compounds |
| JP7377679B2 (ja) * | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法 |
| AU2020257207B2 (en) * | 2019-04-16 | 2026-06-04 | Vivace Therapeutics, Inc. | Bicyclic compounds |
| EP4058435A1 (en) * | 2019-11-13 | 2022-09-21 | Genentech, Inc. | Therapeutic compounds and methods of use |
| EP4065230A1 (en) * | 2019-11-27 | 2022-10-05 | Genentech, Inc. | Therapeutic compounds |
| WO2021120890A1 (en) * | 2019-12-20 | 2021-06-24 | Novartis Ag | Pyrazolyl derivatives useful as anti-cancer agents |
| CN115210227A (zh) * | 2020-03-04 | 2022-10-18 | 基因泰克公司 | 作为tead抑制剂的异双功能分子 |
| WO2021224291A1 (en) * | 2020-05-08 | 2021-11-11 | Merck Patent Gmbh | Tricyclic heterocycles useful as tead binders |
| US11787775B2 (en) * | 2020-07-24 | 2023-10-17 | Genentech, Inc. | Therapeutic compounds and methods of use |
-
2022
- 2022-05-19 AR ARP220101338A patent/AR125921A1/es not_active Application Discontinuation
- 2022-05-19 CN CN202280036206.2A patent/CN117337193A/zh active Pending
- 2022-05-19 TW TW111118775A patent/TW202313048A/zh unknown
- 2022-05-19 EP EP22741119.6A patent/EP4340883A1/en active Pending
- 2022-05-19 WO PCT/US2022/072452 patent/WO2022246459A1/en not_active Ceased
- 2022-05-19 JP JP2023571509A patent/JP2024519845A/ja active Pending
-
2023
- 2023-11-15 US US18/510,227 patent/US20240148733A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7492002B2 (ja) | Lsd1阻害剤によりlsd1関連疾患及び障害を治療する方法 | |
| WO2006080327A1 (ja) | α,α,α-トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤 | |
| NO338380B1 (no) | Anvendelse av et terapeutisk preparat av et PBD-derivat, samt et produkt derav | |
| EA037152B1 (ru) | Способ лечения рака | |
| EA015922B1 (ru) | ВВЕДЕНИЕ ИНГИБИТОРА mTOR ДЛЯ ЛЕЧЕНИЯ ПАЦИЕНТОВ СО ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛЬЮ | |
| AU2007264665B2 (en) | Potentiator of radiation therapy | |
| JP7493503B2 (ja) | Mcl-1阻害剤とミドスタウリンとの組み合わせ、その使用及び医薬組成物 | |
| WO2006069038A1 (en) | Therapeutic materials and methods | |
| WO2021023291A1 (zh) | 原黄素在肺癌治疗中的应用 | |
| JP7311177B2 (ja) | A-NOR-5αアンドロスタン薬物と抗がん薬物との併用 | |
| EP4486345A1 (en) | Method of treatment including kras g12c inhibitors and shp2 inhibitors | |
| JP6549107B2 (ja) | がんの処置のための、ro5503781、カペシタビン及びオキサリプラチンの組み合わせ | |
| MXPA06014477A (es) | Agente antitumor, fortificador de efecto antitumor y metodo de terapia para cancer. | |
| RU2314807C2 (ru) | Комбинированная противоопухолевая терапия, включающая использование замещенных акрилоилпроизводных дистамицина и лучевой терапии | |
| KR20240159340A (ko) | 폐섬유화 예방 또는 치료를 위한 펙시다티닙 및 닌테다닙의 병용 요법 | |
| JP6239745B2 (ja) | がんの処置のための、ro5503781及びカペシタビンの組み合わせ | |
| WO2025214358A1 (zh) | 用于治疗胰腺癌的药物及其用途 | |
| JP5581200B2 (ja) | シチジン誘導体及びカルボプラチンを含有する抗腫瘍剤 | |
| US20090239872A1 (en) | Treatment of mesothelioma | |
| HK40078096A (en) | Methods of treating lsd1-related diseases and disorders with lsd1 inhibitors | |
| AU2003299065A1 (en) | Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes | |
| HK1118704B (en) | Radiotherapy enhancer | |
| HK1118704A1 (en) | Radiotherapy enhancer | |
| HK1148204B (en) | Radiotherapy enhancer | |
| HK1130481B (en) | Potentiator of radiation therapy |